Navigation Links
Ampio Pharmaceuticals, Inc. Appoints New Independent Director

GREENWOOD VILLAGE, Colo., June 8, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a developer of innovative proprietary drugs for metabolic, eye, kidney and CNS disease, male sexual dysfunction, and inflammation, today announced the appointment to its Board of Directors of Dr. David R. Stevens as an additional independent director. Dr. Stevens' appointment, effective immediately, brings the number of independent directors on Ampio's board to four out of six board seats.  

Dr. Stevens is currently executive chairman of Cedus, Inc., a privately-held biopharmaceutical company, and serves on the Board of Directors of Poniard Pharmaceucials, Inc., a public biopharmaceutical company developing and commercializing cancer therapeutics, where he also serves on the Audit and the Nominating and Governance Committees.  In addition, Dr. Stevens is a board member of Micro-Imaging Solutions, LLC, a privately held medical device company, and Aqua Bounty Technologies, a biotechnology company listed on the AIM market of the London Stock Exchange. Dr. Stevens formerly served as president and chief executive officer of Deprenyl Animal Health, Inc., a publicly traded veterinary pharmaceutical company, from 1990 to 1998. Dr. Stevens obtained his Ph.D. in comparative pathology from the University of California, Davis, and his B.S. and D.V.M. degrees from Washington State University.

"On behalf of our board of directors, I would like to welcome Dr. Stevens as our newest board member," said Chief Executive Officer Don Wingerter. "Having personally led and served on the board of directors of a number of biopharmaceutical and medical device companies, Dr. Stevens has a wealth of industry, intellectual property and capital markets experience that our Board believes will prove invaluable as Ampio enters its next stage of growth as a public company."  

Dr. Stevens is being appointed to the Audit and Compensation Committees of the Ampio Board of Directors, replacing Michael Macaluso. Mr. Macaluso continues in his position as Chairman of the Board of Ampio.  

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website,

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, such as changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Relations
Ampio Pharmaceuticals, Inc.

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):